EV/EBITDA Multiple: Biomea (BMEA)

Corporate company logo of biomeafusion.com (BMEA)

The Biomea Fusion, Inc. (BMEA) price chart illustrates the EV/EBITDA multiple, which currently stands at 0.00. Biomea Fusion, Inc. (BMEA) develops cutting-edge pancreatic regeneration drugs, aiming for the complete recovery of diabetes patients. The business relies on the development of specific inhibitors for oncology and endocrinology therapies, where success depends on medical test outcomes. Steady interest in research makes the asset resilient to global economic shocks.

BMEA (Biomea Fusion Inc) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/12/2026

biomeafusion.com (BMEA) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart Biomea|BMEA - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Biomea Fusion Corp|BMEA - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Biomea Fusion|BMEA - Total Net Assets|Market Capitalization to Book Value Ratio biomeafusion.com|BMEA - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Biomea Fusion, Inc.|BMEA - Long-Term Debt to Equity|Short-Term Debt to Equity Biomea Fusion|BMEA - Company Cumulative Debt|Debt to Book Capitalization Ratio Biomea Fusion Corp|BMEA - Company Long-Term Debt|Company Short-Term Debts Biomea Fusion|Quick Liquidity biomeafusion.com
- net income and valuation multiples indicators:
BMEA - Net Financial Result|Expected Profit Biomea Fusion, Inc.|BMEA - Price to Earnings Ratio|Forward P/E Multiple Biomea Fusion, Inc.|BMEA - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Biomea Fusion Corp|BMEA - Operating income before deduction of amortization|Earnings per share for the last twelve months Biomea Fusion|BMEA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months biomeafusion.com|BMEA - Net earnings per share growth this year|Earnings growth forecast for next year Biomea Fusion, Inc.
Initial company analysis:BMEA (Biomea)
Product sample of Biomea Fusion

Biomea Fusion, Inc. (BMEA) is expanding its covalent inhibitor platform to combat metabolic disorders. In this capital-intensive model, the EV/EBITDA chart links market value and debt to operating profit, determining the business value regardless of taxes. It is critical for investors to track the dynamics of this multiple to assess the company's resilience to financial shocks. High volatility on the EV/EBITDA chart signals a shift in market sentiment and the risk of a drawdown.

Who Biomea Fusion, Inc. competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA rhythmtx.com|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Corp|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (soleno.life)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Amicus Therapeutics, Inc. FOLD|89bio Inc (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Pharmaceuticals, Inc.|MBX Biosciences, Inc. (MBX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Altimmune Corp (ALT)|Enterprise Value to EBITDA Ratio Aardvark Pharma AARD|EV/EBITDA Multiple SGMT (Sagimet Biosciences)|bioagelabs.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Quince - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Fractyl Health Inc. GUTS|vtvtherapeutics.com (VTVT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Agape ATP (ATPC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pluristem Therapeutics|Enterprise Value to EBITDA Ratio Synlogic Corp (SYBX)|EV/EBITDA Multiple LPCN|MTNB - Company Value to EBITDA|EV/EBITDA Multiple SPRB (Spruce Biosciences)|EV/EBITDA Multiple Galecto Corporation GLTO|CTCX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation LUMO (lumos-pharma.com)|ONVO: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio RDUS (Radius Recycling Inc.)